Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 348 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
2.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
3.Tiene citas relacionadas Cita con resumen
Diamond D, Kendrick M, Mascitelli L. Exaggerated report of benefits in a flawed long term statin treatment study. BMJ 2017;359:j4915. [Ref.ID 102120]
4.Tiene citas relacionadas Cita con resumen
Ravnskov U, Okuyama H, Sultan S. Serious bias in 20 year follow-up study of statin trial. BMJ 2017;359:j4906. [Ref.ID 102119]
5. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
6.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017;177:966. [Ref.ID 101591]
7.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;177:955-65. [Ref.ID 101590]
8. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
9. Cita con resumen
Anónimo. Lipid-lowering drugs. Med Lett Drugs Ther 2016;58:133-40. [Ref.ID 100944]
10. Cita con resumen
Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]
11. Cita con resumen
Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]
12. Cita con resumen
Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]
13. Cita con resumen
Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014;348:g3244. [Ref.ID 98059]
14.Enlace a cita original
Tonelli M, Wanner Ch, for the Kidney disease: improving global outcomes lipid guideline development work group members. Lipid management in chronick Kidney disease: synopsis of the Kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-93. [Ref.ID 97317]
15. Cita con resumen
Montastruc F. Surveiller nos ordinateurs pur détecter de nouveaux effets indésirables?. BIP31.fr 2013;20:37. [Ref.ID 96648]
16.Tiene citas relacionadas Cita con resumen
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:14. [Ref.ID 95914]
17.Tiene citas relacionadas
Huupponen R, Viikari J. Statins and the risk of developing diabetes. BMJ 2013;346:7. [Ref.ID 95909]
18. Cita con resumen
Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized controlled trials. Circulation: Cardiovascular Quality and Outcomes 2013;6:390-9. [Ref.ID 95648]
19. Cita con resumen
Chung Y-H, Lee Y-C, Chang C-H, Lin M-S, Lin J-W, Lai MS. Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiol Drug Saf 2013;22:583-92. [Ref.ID 95562]
20.Tiene citas relacionadas Cita con resumen
Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg A, Ernst P, Canadian Network for Observational Drug Effect Studies (CNODES). Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:14. [Ref.ID 95407]
Seleccionar todas
 
 1 a 20 de 348 siguiente >>